선택지 정리됨
헌팅턴병: 국가별 치료 선택지
이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.
선택지 정리됨희귀·유전 질환최종 확인 2026.06
국가별 선택지
국가별 치료 선택지
공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.
United States
- Tetrabenazine / Xenazine; deutetrabenazine / Austedo and Austedo XR; valbenazine / Ingrezza and Ingrezza Sprinkle[1]FDA-approvedHuntington disease clinical/genetic diagnosis; CAG expansion confirmation appears in some trial criteria, but VMAT2 labels are symptom/diagnosis framed; Symptomatic treatment of chorea associated with Huntington's disease in adults for deutetrabenazine/valbenazine; chorea associated with Huntington's disease for tetrabenazine. · VMAT2 inhibitor labels include depression/suicidality warnings in Huntington's disease. These medicines address chorea symptoms and do not treat all cognitive, psychiatric, or functional features of Huntington's disease. Confidence/conflicts: High for U.S. label-supported symptomatic chorea options; no disease-modifying claim is made.
European Union
- Tetrabenazine; second-generation neuroleptics/antipsychotics; supportive multidisciplinary care[2]Standard option (per European Medicines Agency)Huntington disease diagnosis; no specific biomarker required for symptomatic chorea guidelines; Symptomatic chorea and behavioral/psychiatric symptom contexts in Huntington's disease. · Guideline article is not a national regulator or reimbursement document. EMA Austedo page fetched this cycle did not support a Huntington indication. UK tetrabenazine source is referenced in a PMDA review report and needs direct MHRA/UK label verification. Confidence/conflicts: Medium-high. Guideline support is verified, but EU/UK national approval and reimbursement require direct labels before patient-facing integration.
Australia
- chorea-directed drug treatment; physiotherapy; assistive equipment and mobility aids; speech and language therapy; psychological support; palliative care[3]Standard option (per Rare Awareness Rare Education Portal / Rare Voices Australia)HTT CAG-repeat expansion; Australian multidisciplinary supportive-care context throughout HD progression. · The RARE Portal is educational, not a drug label, reimbursement rule, or individualized care plan. It does not identify which chorea medicine is approved or funded. Confidence/conflicts: High for Australian supportive-care framing; no conflict identified.
- deutetrabenazine (Austedo)[4]ApprovedHTT CAG-repeat expansion context; chorea associated with Huntington's disease; symptomatic treatment of chorea associated with Huntington's disease. · Austedo is symptomatic; it does not establish a disease-modifying or curative treatment. The product-information attachment states it may have been superseded and current TGA PI should be checked. Confidence/conflicts: High for Australian deutetrabenazine indication in fetched PI attachment; current PI/PBS implementation remains source-pending. Availability/reimbursement outside the approving regulator not established.
Canada
- long-term care supports; outpatient HD clinic/primary care; physical, cognitive, psychiatric, and therapy services[5]Standard option (per Canadian Institute for Health Information)HTT CAG-repeat expansion context; Canadian routine clinic, long-term care, and supportive-service context for adult HD. · CIHI is a health-system analysis, not a prescribing label or individual care guideline. It documents care patterns and gaps but does not define eligibility for specific services. Confidence/conflicts: High for Canadian health-system/supportive-care context; no conflict identified.
- tetrabenazine (Tetrabenazine Tablets; Nitoman class context)[6]ApprovedHuntington's chorea / hyperkinetic movement disorder context; symptomatic treatment of chorea/hyperkinetic movements associated with Huntington disease in Canada. · The product monograph includes major depression/suicidality warnings and contraindications, including active suicidality, untreated or inadequately treated depression, hepatic impairment, MAOI use, and reserpine use. It does not claim disease modification. Confidence/conflicts: Medium-high; tetrabenazine is verified in Canadian monograph context and CIHI national analysis, while brand-specific current DPD details remain a follow-up. Availability/reimbursement outside the approving regulator not established.
출처
- DailyMed / U.S. National Library of Medicine — official drug-label index · official drug-label index
- European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
- Rare Awareness Rare Education (RARE) Portal / Rare Voices Australia — Australian rare-disease educational portal · Australian rare-disease educational portal
- Therapeutic Goods Administration (TGA) / Teva Pharma Australia — AusPAR product-information attachment · AusPAR product-information attachment
- Canadian Institute for Health Information (CIHI) — national health system analysis · national health system analysis
- Health Canada / SteriMax product monograph repository — official product monograph · official product monograph
위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026.06.
승인된 치료 너머
임상시험 및 신흥 선택지
환자가 거주하는 국가에서 아직 승인된 표준 치료가 아닌 선택지입니다 — 연구, 임상시험, 허가 외 사용, 담당 종양내과 의사가 먼저 언급하지 않을 수 있는 초기 근거입니다. 각 항목은 근거의 강도에 따라 구분됩니다. 여기에 실린 항목은 조사하고 의료진과 상의할 정보일 뿐, 효과가 입증되었거나 안전하거나 현재 이용 가능하다는 의미가 아닙니다. 임상 세부 내용은 영문이 정본입니다.
임상시험 진행 중
- AMT-130 intra-striatal rAAV5-miHTT; RO7234292/RG6042 intrathecal therapy; WVE-120101임상시험 · NCT04120493임상시험Trial only (registry)United States · HTT CAG expansion at least 40 repeats for AMT-130; targeted SNP1 rs362307 for WVE-120101 extension; manifest Huntington disease criteria for RO7234292 extension; Early manifest Huntington's disease for AMT-130; prior Roche/Genentech study participants for RO7234292 extension; prior WVE-HDSNP1-001 completers with targeted SNP1 context for WVE-120101 extension. · WVE-120101 record is terminated; RO7234292 record is completed; AMT-130 is active-not-recruiting in the fetched record. Trial-specific neurosurgical/intrathecal risks and eligibility are not generalized. Confidence/conflicts: High for registry status and geography; no approval claim is made. ClinicalTrials.gov — clinical-trial registry
- SD-809/deutetrabenazine extended release; transcranial direct-current stimulation (tDCS); sham comparator임상시험 · NCT01897896임상시험Trial only (registry)United States · Manifest Huntington disease with expanded CAG repeat in deutetrabenazine trial; confirmed HD mutation and/or family history plus symptoms in tDCS trial; Chorea associated with Huntington disease for SD-809/deutetrabenazine extension/switch trial; cognitive and behavioral symptoms for tDCS pilot feasibility study. · tDCS is trial-framed and not recorded as routine treatment. ARC-HD is completed and supports registry evidence, not current enrollment. Confidence/conflicts: High for trial records; no routine tDCS availability claim is made. ClinicalTrials.gov — clinical-trial registry
- pridopidine임상시험임상시험InvestigationalCanada · clinical HD with at least 36 CAG repeats in the huntingtin gene per trial inclusion; adults aged 25 years and older with adult-onset stage 1 or 2 HD in a clinical-trial context. · Trial listing does not establish approval, efficacy, disease modification, or individual eligibility. The source points to ClinicalTrials.gov for most recent updates. Confidence/conflicts: Medium-high for Canadian trial listing; current ClinicalTrials.gov status should be rechecked before patient-facing reuse. Huntington Society of Canada — clinical-trial listing / patient organization trial page
임상시험이나 초기 보고에 실렸다는 것은 해당 선택지가 연구되고 있다는 의미일 뿐, 효과가 있거나 특정 환자에게 안전하거나 현재 등록 가능하다는 뜻은 아닙니다. 어떤 선택지가 적합한지는 담당 종양내과 팀과 임상시험 팀이 함께 상의할 문제입니다. 최종 확인 2026.06.
현재 제공
국가별 선택지를 정리합니다
국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.
아직 하지 않음
치료 선택을 지시하지 않습니다
이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.
출처
공신력 있는 출처 기반
모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.
진료 전 정리할 정보
- Is chorea the symptom being targeted, or are mood, cognition, sleep, swallowing, or behavior the priority?
- Are depression or suicidality risks being actively assessed before VMAT2 inhibitor use?
- Is the planned VMAT2 inhibitor covered by the local formulary or insurance plan?
- Are chorea, psychiatric symptoms, or swallowing/falls driving the treatment decision?